curcumin for endometriosis
A single systematic review reports that curcumin shows beneficial effects on endometriosis pathophysiology, indicating potential therapeutic application.
Hypothesized mechanism
Curcumin may favorably modulate the pathophysiology of endometriosis, though the specific mechanism is not detailed in the provided claim.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 7 of 10 overall, a moderate reading, from a direct rated moderate in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Evidence comes from a single systematic review ("Impact of curcumin, quercetin, or resveratrol... A systematic review"). A single synthesis scores 1 and is not independent replication; the pooled trials inside it do not count as independent sources.
Rigor
The source is a systematic review, which qualifies as a higher-rigor design (meta-analysis/systematic review = 2). However, the review covers preclinical/mechanistic studies, which tempers the practical weight of the score.
Specificity
Both the intervention (curcumin) and the condition (endometriosis) are named directly in the claim and quote: "potential application in the endometriosis treatment." The specificity is clear.
Plausibility
The claim asserts beneficial effects on the pathophysiology of endometriosis but does not detail an evidenced mechanism in the provided quote. This supports plausibility but not a fully evidenced mechanistic chain.
Consistency
Only a single source (one systematic review) is provided, so directional agreement across independent studies cannot be assessed. Per rubric, a single source defaults to 1.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1curcumin, quercetin, and resveratrol showed to have beneficial effects, evidencing their potential application in the endometriosis treatment PubMed · PMID 35583746 ↗
- 2In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 1 report(s) of ABDOMINAL DISTENSION were recorded for curcumin among female patients (of 76 female reports for curcumin in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests curcumin acts on a system relevant to endometriosis — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
- 3In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 1 report(s) of ABDOMINAL PAIN were recorded for curcumin among female patients (of 76 female reports for curcumin in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests curcumin acts on a system relevant to endometriosis — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →